Quantum-Si (NASDAQ:QSI) CEO Jeffrey Alan Hawkins Sells 11,310 Shares of Stock

Quantum-Si Incorporated (NASDAQ:QSI) CEO Jeffrey Alan Hawkins sold 11,310 shares of Quantum-Si stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $0.96, for a total transaction of $10,857.60. Following the transaction, the chief executive officer directly owned 3,681,113 shares of the company’s stock, valued at $3,533,868.48. The trade was a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jeffrey Alan Hawkins also recently made the following trade(s):

• On Tuesday, June 23rd, Jeffrey Alan Hawkins sold 11,311 shares of Quantum-Si stock. The shares were sold at an average price of $0.90, for a total transaction of $10,179.90.
• On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The shares were sold at an average price of $1.01, for a total transaction of $84,549.12.

Quantum-Si Trading Down 6.0%

Quantum-Si stock opened at $0.83 on Thursday. The firm has a 50-day moving average price of $0.99 and a 200-day moving average price of $1.04. The firm has a market capitalization of $180.13 million, a PE ratio of -1.62 and a beta of 3.18. Quantum-Si Incorporated has a 12-month low of $0.69 and a 12-month high of $3.10.

Quantum-Si (NASDAQ:QSI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, sell-side analysts predict that Quantum-Si Incorporated will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Prudential Financial Inc. bought a new stake in Quantum-Si during the 2nd quarter valued at about $25,000. Curbstone Financial Management Corp bought a new position in Quantum-Si in the 4th quarter worth about $26,000. Leonteq Securities AG bought a new position in Quantum-Si in the 4th quarter worth about $28,000. Cerity Partners LLC purchased a new position in shares of Quantum-Si during the second quarter worth approximately $29,000. Finally, Hollencrest Capital Management boosted its holdings in shares of Quantum-Si by 301.1% in the first quarter. Hollencrest Capital Management now owns 40,111 shares of the company’s stock valued at $31,000 after purchasing an additional 30,111 shares during the period. Hedge funds and other institutional investors own 39.90% of the company’s stock.

Analysts Set New Price Targets

QSI has been the topic of several recent analyst reports. Canaccord Genuity Group reduced their price target on Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Quantum-Si in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Quantum-Si currently has an average rating of “Reduce” and an average target price of $1.00.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.